Best Medical & Healthcare
Trust Us To Be There To Help All & Make Things Well Again
Rooted in Deep Scientific, Clinical and Operational Expertise
Meet the Leadership Team Behind KAD Clinical Research
Kristina Wriston,
BSN, RN, CCRC
CEO
Kristina Wriston, BSN, RN, CCRC, brings over two decades of experience working with pharmaceutical companies and CROs to develop business opportunities across Phase I through IV clinical trials. She has been a Sub-Investigator in more than 110 clinical trials, demonstrating hands-on expertise and a steadfast commitment to advancing medical research.
As a former Site Director of Operations, Kristina excelled in managing clinical trial activities, ensuring compliance with SOPs, ICH, and GCP guidelines, and overseeing trial metrics. She brings a strong foundation in scientific methods, research, and compliance, complemented by a deep passion for innovation that drives her success in advancing clinical trial excellence.
Adrian M. Di Bisceglie,
MD, FACP, FAASLD
CMO
Adrian Michael Di Bisceglie, MD, FACP, FAASLD, has been a consultant to biotech and pharmaceutical companies for more than 30 years now. He is a prominent hepatologist who served as President of AASLD in 2014 and was a long-time department chairman at Saint Louis University.
He has published extensively in liver disease with an emphasis on viral hepatitis and hepatocellular carcinoma. After his time in academia, Dr. Di Bisceglie served as Chief Medical Office for HighTide Therapeutics from 2019 to 2023 and has since then devoted himself exclusively to consulting. He has developed special expertise in metabolic diseases, including MASH, diabetes and hyperlipidemia, viral hepatitis, hepatocellular carcinoma, end-stage liver disease and the use of targeted therapeutic peptides. Dr. Di Bisceglie has established referral networks throughout the United States and abroad, in hepatology and multiple other disciplines and has served as an advisor to the National Institutes of Health, the Centers for Disease Control and Prevention and
the Food and Drug Administration.
Derek Vanover,
Esq
General Counsel
Derek Vanover, Esq brings ten years of legal and business acumen, much of that time devoted to assisting sponsors in navigating the unique challenges of drug development. Derek served three years as in-house counsel at a CRO and since in fractional counsel roles for various biotech, pharma, and medical device companies.
At KAD, Derek works to make legal processes straightforward and practical, helping sponsors and CROs work more effectively together.